导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.04% | 3312/4773 |
| 近一周 | -1.68% | 2516/5465 |
| 近一月 | 1.24% | 325/5421 |
| 近一季 | 3.81% | 422/5231 |
| 近半年 | -2.68% | 2237/4920 |
| 近一年 | -3.70% | 3115/4394 |
| 近两年 | 25.19% | 2499/2954 |
| 近三年 | 21.37% | 1430/2253 |
| 成立以来 | 47.51% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.24% 3573/4961 |
-9.05% 3939/5312 |
- - |
- - |
| 2025 | 5.46% 2998/4813 |
-2.62% 2933/3635 |
5.90% 527/4076 |
-0.27% 3922/4524 |
2.54% 917/4813 |
| 2024 | 30.88% 105/3463 |
8.60% 177/2808 |
3.36% 272/3014 |
17.12% 1271/3129 |
-0.44% 1425/3463 |
| 2023 | 1.90% 339/2656 |
5.11% 829/2280 |
3.20% 101/2385 |
2.12% 255/2515 |
-8.02% 2235/2655 |
| 2022 | -2.62% 59/2207 |
-1.06% 137/1919 |
1.72% 1432/2016 |
-7.17% 116/2113 |
4.23% 572/2208 |
| 2021 | -2.81% 872/1822 |
3.30% 188/1255 |
-5.05% 1270/1330 |
-1.35% 520/1466 |
0.44% 1111/1822 |
| 2020 | 5.65% 879/1250 |
-12.48% 888/1028 |
2.56% 967/1067 |
9.54% 643/1164 |
7.45% 711/1184 |
| 2019 | - - |
- - |
- - |
-2.07% 685/850 |
5.53% 707/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实中证锐联基本面ETF VS. 长安沪深300非周期A(740101) |